Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.41 |
| ▸ | LOX | P28300 | 1/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.38 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.37 |
| ▸ | MGLL | Q99685 | 1/20 | 0.36 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.36 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.36 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
| ▸ | AR | P10275 | 1/20 | 0.35 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.35 |
| ▸ | ACACB | O00763 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20786041 | 0.81 | LOXL2 (0.44) | LOXL2LOXMGLLSMARCA2SMARCA4 | |
| SCHEMBL25777933 | 0.80 | LOXL2 (0.40) | LOXL2LOXPDE4BLRRK2MGLL | |
| SCHEMBL22585782 | 0.79 | CYP17A1 (0.45) | LOXL2LOXMGLLSMARCA2SMARCA4 | |
| SCHEMBL27480574 | 0.78 | LOXL2 (0.38) | LOXL2LOXPDE4BLRRK2MGLL | |
| SCHEMBL22586037 | 0.78 | LOXL2 (0.46) | LOXL2LOXSMARCA2SMARCA4NOTUM | |
| SCHEMBL11790109 | 0.77 | LOXL2 (0.49) | LOXL2LOXSMARCA2SMARCA4NOTUM | |
| SCHEMBL27372410 | 0.77 | LOXL2 (0.49) | LOXL2LOXSMARCA2SMARCA4NOTUM | |
| SCHEMBL179263 | 0.77 | LOXL2 (0.47) | LOXL2LOXMGLLSMARCA2SMARCA4 | |
| SCHEMBL27268905 | 0.76 | MALT1 (0.34) | LOXL2LOXPDE4BLRRK2MGLL | |
| SCHEMBL21098120 | 0.75 | NOS3 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240217964-A1 | QUINUCLIDINONE ANALOGUES AS ANTICANCER AGENTS | NEWAVE PHARMACEUTICAL INC. | 2024-07-04 | — | — | US | disclosed |
| US-20230089530-A1 | QUINUCLIDINONE ANALOGUES AS ANTICANCER AGENTS | NEWAVE PHARMACEUTICAL INC. | 2023-03-23 | — | — | US | disclosed |
| EP-4100407-A1 | QUINUCLIDINONE ANALOGUES AS ANTICANCER AGENTS | Newave Pharmaceutical Inc. (US) | 2022-12-14 | — | — | EP | disclosed |
| WO-2022204109-A1 | QUINUCLIDINONE ANALOGUES AS ANTICANCER AGENTS | NEWAVE PHARMACEUTICAL INC. (US) | 2022-09-29 | — | — | WO | disclosed |
| WO-2021158948-A1 | QUINUCLIDINONE ANALOGUES AS ANTICANCER AGENTS | NEWAVE PHARMACEUTICAL INC. (US) | 2021-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230089530-A1 | QUINUCLIDINONE ANALOGUES AS ANTICANCER AGENTS | NQO2, CNKSR1, NQO1 | LOXL2 3566/4885LOX 3887/4885PDE4B 2189/4885 |
| US-20240217964-A1 | QUINUCLIDINONE ANALOGUES AS ANTICANCER AGENTS | NQO2, PRMT1, PRMT7 | LOXL2 3833/4885LOX 4077/4885PDE4B 2419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.